Clinical Trial

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Study acronym: ARCHER II
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-07-15; most recent amendment 2026-04-28.
Status change: Recruiting → Active, Not Recruiting 2025-11-05
Status change: Not Yet Recruiting → Recruiting 2024-08-30
Trial Details
NCT Number NCT06510816
Lead Sponsor Annexon, Inc.
Conditions Geographic Atrophy
Enrollment 659 participants
Start Date 2024-07-30
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04